Granulomatosis with polyangiitis (GPA) is a form of vasculitis—a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. Formerly called Wegener’s granulomatosis, GPA typically affects the sinuses, lungs, and kidneys but can also involve other tissues and organs. GPA can worsen rapidly, so early diagnosis and treatment are essential to prevent organ damage or failure.

In early stages, GPA symptoms resemble a common cold with persistent runny nose and nasal congestion, but may include nosebleeds, shortness of breath, coughing up blood, sinus pain, hoarseness or middle ear symptoms. Besides potential damage to the kidneys and respiratory tract, other serious complications may include vision or hearing loss, heart disease, and stroke.

GPA is a potentially serious but treatable disease. Corticosteroids such as prednisone are used in combination with medications that suppress the immune system, to control inflammation. Even with effective treatment, relapse can occur, so ongoing medical follow-up is usually necessary.

**Causes**
The cause of GPA is not yet fully understood by researchers. Vasculitis is classified as an autoimmune disorder, a disease which occurs when the body’s natural defense system mistakenly attacks healthy tissues. Abnormal function of white blood cells (neutrophils) is thought to be involved in the disease.

Researchers believe an infection may contribute to the onset of GPA, but it is unlikely that an infection alone can explain this complex disorder. Environmental and genetic factors may play a role as well. Research is ongoing, but so far, no specific infectious, genetic, or environmental factor has been conclusively associated with GPA.

**Who gets GPA?**
GPA affects an estimated 3 out of every 100,000 people. Although the disorder can occur at any age, onset is usually between 40 and 65 years of age, affecting males and females in equal numbers. The disease is rare in children but does occur. GPA can affect people of any race or ethnic background but appears to mostly affect Caucasians. Because GPA often goes unrecognized, researchers believe it is underdiagnosed, making it difficult to accurately determine its frequency.

**Symptoms**
The symptoms of GPA can vary greatly from person to person. For some, the disease is mild, while for others it may be severe or even potentially life-threatening. GPA symptoms may come on slowly over a period of months, or develop rapidly in a matter of days. Early symptoms can include:

- Runny nose/nasal congestion
- Nosebleeds
- Sinus pain
- Ear pain/hearing loss
- Shortness of breath
GRANULOMATOSIS WITH POLYANGIITIS

- Coughing up blood
- Hoarseness

Other symptoms include:

- Fever
- Fatigue
- Joint pain
- Loss of appetite/weight loss
- Eye problems
- Skin sores
- Night sweats
- Numbness in the fingers, toes, or limbs
- Kidney problems (Note: Kidney disease can be present without symptoms; therefore, patients with vasculitis should have regular urine tests.)

Serious complications may occur, including inflammation, bleeding and scarring of the lungs, kidney damage or failure, heart disease, hearing loss, skin scarring, deep vein thrombosis (blood clot), or damage to the bridge of the nose from weakened cartilage.

See your doctor if you have cold symptoms that don’t get better with over-the-counter cold medications, especially if you have nosebleeds, are coughing up blood or have other warning signs.

Diagnosis
There is no single test for diagnosing GPA, so your doctor will consider a number of factors, including symptoms, medical history, physical exam findings, laboratory tests, and imaging studies. A biopsy of the affected tissue is sometimes required to confirm the diagnosis.

Urine tests: A urinalysis can detect red blood cells or excess protein in the urine, which can indicate whether the kidneys are being affected.

Blood tests: The most common blood test for GPA checks for an antibody called ANCA, or anti-neutrophil cytoplasmic antibody. The ANCA test is positive in most individuals with GPA, so it may help support a suspected diagnosis of GPA. However, a positive test alone does not confirm diagnosis.

Imaging studies: Chest X-rays can show changes in the lungs. Computed tomography (CT) scans and magnetic resonance imaging (MRI) provide more detailed images of the internal organs and can reveal abnormalities in the sinuses, chest, brain, blood vessels or abdominal organs.

Tissue biopsy: This surgical procedure removes a small tissue sample from an affected organ, such as the lung, kidney, skin or sinuses, which is examined under a microscope for signs of inflammation or tissue damage.
**GRANULOMATOSIS WITH POLYANGIITIS**

**Treatment**
The course of treatment for GPA depends on the organs affected and disease severity. Patients with milder disease are commonly prescribed corticosteroids such as prednisone, in combination with an immunosuppressant drug called methotrexate, to control inflammation.

Patients with severe disease may be prescribed the biologic drug rituximab, used in conjunction with corticosteroids. Rituximab was approved in 2011 by the U.S. Food and Drug Administration for the treatment of GPA and another form of vasculitis, microscopic polyangiitis. Biologic medications are complex proteins derived from living organisms. Biologics target certain parts of the immune system to control inflammation.

Another option for those with severe disease is cyclophosphamide—a chemotherapy-type drug that blocks abnormal growth of certain cells in the body. It is used in combination with prednisone. Cyclophosphamide is usually limited to a three- to six-month period, then replaced with less toxic drugs such as methotrexate, mycophenolate mofetil, or azathioprine.

Once the disease is in remission, patients will need to continue taking maintenance medications, such as azathioprine, methotrexate or rituximab, to keep the disease under control. The dose of steroids is usually tapered during remission.

Some individuals may experience kidney failure, a serious complication that requires dialysis and/or a kidney transplant. Finally, an option for those with very serious GPA affecting the kidneys or lungs is “plasmapheresis.” Plasmapheresis is a dialysis-like procedure that clears proteins from the plasma of the blood and replaces it with plasma from a donor, or with a plasma substitute.

**Side effects**
The medications used to treat GPA have potentially serious side effects, such as lowering your body’s ability to fight infection, and potential bone loss (osteoporosis), among others. Therefore, it’s important to see your doctor for regular checkups. Medications may be prescribed to offset side effects. Infection prevention is also very important. Talk to your doctor about getting a flu shot, pneumonia vaccination, and/or shingles vaccination, which can reduce your risk of infection.

**Relapse**
GPA is a chronic disease with periods of relapse and remission. If your initial symptoms return or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring of lab and imaging tests are important in detecting relapses early.

**Your medical team**
Effective treatment of GPA may require the coordinated efforts and ongoing care of a team of medical providers and specialists. In addition to a primary care provider, you may need to see the following specialists: rheumatologist (joints, muscles, and immune system); pulmonologist (lung); otolaryngologist (ear, nose and throat); nephrologist (kidneys); dermatologist (skin); cardiologist (heart); neurologist (brain/and nervous system); or others as needed.
GRANULOMATOSIS WITH POLYANGIITIS

The best way to manage your disease is to actively partner with your health care providers. Get to know the members of your health care team. It may be helpful to use a health care journal to keep track of medications, symptoms, test results and notes from doctor appointments. To get the most out of your doctor visits, make a list of questions beforehand and bring along a supportive friend or family member to provide a second set of ears and take notes.

Remember, it’s up to you to be your own advocate. If you have concerns with your treatment plan, speak up. Your doctor may be able to adjust your dosage, or offer different treatment options. It is always your right to seek a second opinion.

Living with GPA
Living with a chronic disease such as GPA can be challenging at times. Fatigue, pain, emotional stress, and medication side effects can take a toll on your sense of well-being, affecting relationships, work and other aspects of your daily life. Sharing your experience with family and friends, connecting with others through a support group, or talking with a mental health professional can help.

Outlook
There is no cure for GPA at this time, but early diagnosis and effective treatment can bring the disease into remission, and many patients can lead full, productive lives. Left untreated, GPA can lead to potentially life-threatening organ damage or failure. Even with treatment, many patients will experience periods of relapse, so ongoing medical care is important.

Clinical studies are ongoing at multicenter research centers, including the Vasculitis Clinical Research Consortium (VCRC), to better understand the risk factors and causes of vasculitis, investigate more effective and safer treatments, and work toward a cure. The Vasculitis Foundation encourages patients to consider participating in clinical research studies to help further understanding of vasculitis. Patients are also encouraged to join the Vasculitis Patient-Powered Research Network (VPPRN), where they can provide valuable disease insight and information.

For more information on vasculitis research, visit: www.vasculitisfoundation.org/research
GRANULOMATOSIS WITH POLYANGIITIS

About Vasculitis
Vasculitis is a family of nearly 20 rare diseases characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. Vasculitis is classified as an autoimmune disorder, which occurs when the body’s natural defense system mistakenly attacks healthy tissues. Triggers may include infection, medication, genetic or environmental factors, allergic reactions, or another disease. However, the exact cause is often unknown.

A Family of Diseases
- Anti-GBM (Goodpasture’s) disease
- Aortitis
- Behcet’s syndrome
- Central nervous system vasculitis
- Cogan’s syndrome
- Cryoglobulinemia
- Cutaneous small-vessel vasculitis (formerly hypersensitivity/leukocytoclastic)
- Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome)
- Giant cell arteritis
- Granulomatosis with polyangiitis (GPA, formerly Wegener’s)
- IgA vasculitis (Henoch-Schönlein Purpura)
- Kawasaki disease
- Microscopic polyangiitis
- Polyarteritis nodosa
- Polymyalgia rheumatica
- Rheumatoid vasculitis
- Takayasu’s arteritis
- Urticarial vasculitis

About the Vasculitis Foundation
The Vasculitis Foundation (VF) is the leading organization in the world dedicated to diagnosing, treating, and curing all forms of vasculitis. The VF provides a wide range of education, awareness and research programs and services. To learn more, and get the most updated disease and treatment information, visit www.vasculitisfoundation.org

Connect with the VF on Social Media
- Instagram: vasculitisfoundation
- Twitter: @VasculitisFound
- VF Facebook Discussion Group: www.facebook.com/groups/vasculitisfoundation
GRANULOMATOSIS WITH POLYANGIITIS

Ways to Get Involved

• Participate in research
• Join social media
• Host or participate in an event
• Attend a regional conference and/or symposium
• Give a donation toward long-term solutions
• Become an advocate for yourself, or for others
• Share your journey

Vasculitis Foundation Mission
Building upon the collective strength of the vasculitis community, the Foundation supports, inspires and empowers individuals with vasculitis, and their families, through a wide range of education, research, clinical, and awareness initiatives.

Join the VPPRN!
The Vasculitis Patient-Powered Research Network (VPPRN) seeks to improve the care and health of patients with vasculitis by exploring research questions that matter most to patients, and by advancing medical knowledge about vasculitis. For more information, visit: www.VPPRN.org

The Vasculitis Clinical Research Consortium (VCRC) is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different forms of vasculitis. For more information, visit: www.rarediseasesnetwork.org/cms/vcrc

Vasculitis Foundation
PO Box 28660
Kansas City, Missouri, 64188-8660
USA
Phone: 816.436.8211
Toll-free: 800.277.9474
Fax: 816.656.3838
www.VasculitisFoundation.org
Email: vf@vasculitisfoundation.org

The VF gratefully acknowledges Eric Matteson, MD, Mayo Clinic, for his expertise and contribution to this brochure. This brochure was supported by an unrestricted education grant from Genentech. The Vasculitis Foundation is solely responsible for all content.

The Vasculitis Foundation (VF) is a 501(c)(3) nonprofit organization governed by a Board of Directors and advised on medical issues by a Medical and Scientific Advisory Board. VF’s educational materials are not intended to replace the counsel of a physician. VF does not endorse any medications, products or treatments for vasculitis, and advises you to consult a physician before initiating any treatment.

(Updated October 2018)